Aim To analyse frequency of chronic obstructive pulmonary disease (COPD) exacerbation in patients on therapy with inhaled corticosteroids (ICS) and relevant factors that influence the rate of COPD exacerbations in a subgroup of moderate illness, like FEV1, comorbidities and other concomitant therapy. Methods The study included patients with moderate COPD with at least 10 pack-years history of smoking and accompanying cardiovascular comorbidity. Demographic data, frequency of exacerbations and information about proscribed treatments-ICS alone or in combination with long acting beta agonist (LABA), were collected from medical records for the previous 12 months from the index date. Results Data were collected for 210 patients (170 males) with the mean age 65.63±8.66 years, 72 of which were treated with a fixed combination of long acting beta blocker (LABA) and ICS. Significantly more frequent exacerbations were detected in patients using ICS p<0.0001) and having higher Modified British Medical Research Council (mMRC) score p=0.004). No statistically significant difference was registered related to ratio of FEV 1 /FVC (p=0.121) or a number of cardiovascular comorbidities per patient (p=0.969). Conclusions: Our results present a small contribution to the current scientific discussion about the use of ICS in COPD treatment. Further prospective studies are needed to confirm the impact of ICS on the frequency of COPD exacerbations.
Guariscio J, Ray M, Finch K, Self H. The clinical and economic burden of chronic obstructive pulmonary disease in USA. Clinicoecon Outcomes Res. 2013;5235–45.
2.
Blanchette M, Gross J, Altnam P. Rising costs of COPD and the potential for maintenance therapy to slow the trend. Am Health Drug Benefits. 2014;98–106.
3.
Negro D, R. Optimizing economic outcomes in the management of COPD. Int J Chron Obstruct Pulmon Dis. 2008;1–10.
4.
Punekar S, Landis H, Wurst K, Lee H. Characteristics, disease burden and costs of COPD patients in two year following initiation of long-acting bronchodilators in UK Primary Care. Respir Res. 2015;141.
5.
Global Initiative for Chronic Obstructive Lung Disease, Inc. 2017;
6.
Chupp G, Bradford E, Albers F, Bratton D, Wang-Jairaj J, Nelsen L, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomized, double-blind, placebocontrolled, parallel group, multicentre, phase 3b trial. Lancet Respir Med. 2017;390–400.
7.
Dekhuijzen P, Batsiou M, Bjermer L, Bosnic-Anticevich S, Chrystyn H, Papi A, et al. Incidence of oral thrush in patients with COPD prescribed inhaled corticosteroids: Effect of drug, dose, and device. Respir Med. 2016;54–63.
8.
Suissa S, Patenaude V, Lapi F, Ernst P. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax. 2013;1029–36.
9.
Mullerova H, Maskell J, Meeraus W, Galkin D, Albers F, Gait C. Characterization of COPD patients treated with inhaled triple therapy containing inhaled corticosteroids [ICS], long-acting beta2agonists [LABA], and long-acting muscarinic antagonists [LAMA] in the UK. Am J Respir Crit Care Med. 2017;A4986.
10.
Siddiqui S, Guasconi A, Vestbo J, Jones P, Agusti A, Paggiaro P, et al. Blood eosinophils: a biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;523–5.
11.
Pavord I, Lettis S, Locantore N, Pascoe S, Jones P, Wedzicha J, et al. Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD. Thorax. 2016;118–25.
12.
Bafadhel M, Davies L, Calverley P, Aaron S, Brightling C, Pavord I. Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis. Eur Respir J. 2014;789–91.
13.
Global Initiative for Chronic Obstructive Lung Disease. 2010;
14.
Launois C, Barbe C, Bertin E, Nardi J, Perotin J, Dury S, et al. The modified Medical Research Council scale for the assessment of dyspnea in daily living in obesity: a pilot study. BMC Pulmonary Medicine. 2012;61.
15.
Classes of Heart Failure. 10AD;
16.
Calverley P, Anderson J, Celli B, Ferguson G, Jenkins C, Jones P, et al. TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.
17.
N Engl J Med. 2007;775–89.
18.
Andell P, Koul S, Martinsson A, Sundstrom J, Jernberg T, Smith J, et al. Impact of chronic obstructive pulmonary disease on morbidity and mortality after myocardial infarction. Open Heart. 2014;2.
19.
Horse F, Kiljander T, Lehtimaki L. Annual costs of chronic obstructive pulmonary disease in Finland during 1996-2006 and prediction model for 2007-2030. NPJ Prim Care Respir Med. 2015;15015.
20.
Dalal A, Christensen L, Liu F, Riedel A. Direct costs of chronic obstructive pulmonary disease among managed care patients. Clinicoecon Outcomes Res. 2010;341–9.
21.
Shina S, Gurm H. The double jeopardy of chronic obstructive pulmonary disease and myocardial infarction. Open Heart. 2014;10.
22.
Ortega H, Liu M, Pavord I, Brusselle G, Fitz-Gerald J, Chetta A, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;1198–207.
23.
Nadeem N, Taylor S, Eldridge S. Withdrawal of inhaled corticosteroids in individuals with COPD -a systematic review and comment on trial methodology. Respir Res. 2011;107.
24.
Dhanalakshmi D, Savya S, Kumar S, Murthy K, Sowmya M, J. Relationship between dyspnea MMRC Scale and Forced Expiratory Volume in First Second (FEV1) in chronic obstructive pulmonary disease. Sch J App Med Sci. 2016;3544–7.
25.
Bhanurekha B, Sasisekhar T, Saireddy Y. Indrakeela Girish M. Correlation of MRC dyspnoea scale and forced expiratory volume in first second (FEV1) in chronic obstructive pulmonary diseases. IOSR Journal of Dental and Medical Sciences. 2013;55–7.
26.
Yancey S, Albers F, Gunsoy N, Harris S, Keene O. Effect of mepolizumab on exacerbations in asthma patients with features common in COPD. Am J Respir Crit Care Med. 2017;4683.
27.
Vestbo J, Papi A, Corradi M, Blazhko V, Montagna I, Francisco C, et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomized controlled trial. Lancet. 2017;1919–29.
28.
Sharafkhaneh A, Southard J, Goldman M, Uryniak T, Martin U. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study. Respir Med. 2012;257–68.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
